Accera Venture Partners

Cerecin, formerly known as Accera, is a clinical-stage biotechnology company specializing in the development of metabolic therapies for brain health. The company's primary focus is on addressing the glucose hypometabolism associated with neurodegenerative diseases by providing ketone bodies as an alternative energy source. Its lead product candidate, tricaprilin, is being investigated in Phase 3 trials for Alzheimer's disease and Phase 2 trials for other neurological conditions like migraine and infantile spasms. Cerecin is headquartered in Singapore and maintains a global presence in the neuro-metabolism research space, building on its history of developing the medical food Axona.